Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery ...

LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable ...

Key Points Revenue (GAAP) exceeded analyst estimates by 10.2% for Q2 2025, with GAAP net revenue rising to $10.3 million, driven by growth in LOQTORZI sales. Non-GAAP EPS missed expectations at $(0.34 ...

LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 -- Data readouts for CHS-114 and casdozokitug on track for 1H 2026 -- Q2 2025 ending cash, cash equivalents and marketable ...

Machine learning model predicts radiotherapy response in nasopharyngeal carcinoma patients using gene expression data.